Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin

William E. Dager, Jeff H. King, Ron C. Regalia, Dean Williamson, Robert C. Gosselin, Richard H White, R. Steven Tharratt, Timothy E Albertson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Study Objective. To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events. Design. Prospective observational study. Setting. Intensive care unit of a 500-bed university-affiliated hospital. Patients. Sixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event. Intervention. Patients received rFVIIa 1.2 mg for reversal of anticoagulation. Measurements and Main Results. Patients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross-checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean ± SD dose of rFVIIa 16.3 ± 4.1 μg/kg (range 11-25 μg/kg) reduced the mean INR from 2.8 ± 1.6 (range 1.44-6.34) to 1.07 ± 0.27 (range 0.86-1.92, p<0.001). A rapid onset of response for achieving a desirable hemostatic effect was observed in 14 of the 16 patients. Conclusion. Low-dose rFVIIa appears to be an effective, rapid reversal modality for major bleeding events in the presence of warfarin and an elevated INR. The agent's response is quicker than that expected with fresh frozen plasma combined with vitamin K. In emergency situations, rFVIIa 1.2 mg can be used to reverse the anticoagulant effect of warfarin and other vitamin K antagonists without inducing a hypercoagulable state; the product, however, is expensive.

Original languageEnglish (US)
Pages (from-to)1091-1098
Number of pages8
JournalPharmacotherapy
Volume26
Issue number8 I
DOIs
StatePublished - Aug 2006

Fingerprint

Factor VIIa
International Normalized Ratio
Warfarin
Hemorrhage
Vitamin K
Clinical Pharmacology
Hemostatics
Information Systems
Critical Illness
Anticoagulants
Observational Studies
Intensive Care Units
Emergencies
recombinant FVIIa
Prospective Studies

Keywords

  • Anticoagulation reversal
  • Bleeding
  • Fresh frozen plasma
  • INR
  • International normalized ratio
  • Intracranial hemorrhage
  • NOVOSEVEN
  • Recombinant activated factor VII
  • rFVIIa
  • Trauma
  • Warfarin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. / Dager, William E.; King, Jeff H.; Regalia, Ron C.; Williamson, Dean; Gosselin, Robert C.; White, Richard H; Tharratt, R. Steven; Albertson, Timothy E.

In: Pharmacotherapy, Vol. 26, No. 8 I, 08.2006, p. 1091-1098.

Research output: Contribution to journalArticle

Dager, William E. ; King, Jeff H. ; Regalia, Ron C. ; Williamson, Dean ; Gosselin, Robert C. ; White, Richard H ; Tharratt, R. Steven ; Albertson, Timothy E. / Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. In: Pharmacotherapy. 2006 ; Vol. 26, No. 8 I. pp. 1091-1098.
@article{2b9e5090966b44f8b6b15cb366141375,
title = "Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin",
abstract = "Study Objective. To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events. Design. Prospective observational study. Setting. Intensive care unit of a 500-bed university-affiliated hospital. Patients. Sixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event. Intervention. Patients received rFVIIa 1.2 mg for reversal of anticoagulation. Measurements and Main Results. Patients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross-checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean ± SD dose of rFVIIa 16.3 ± 4.1 μg/kg (range 11-25 μg/kg) reduced the mean INR from 2.8 ± 1.6 (range 1.44-6.34) to 1.07 ± 0.27 (range 0.86-1.92, p<0.001). A rapid onset of response for achieving a desirable hemostatic effect was observed in 14 of the 16 patients. Conclusion. Low-dose rFVIIa appears to be an effective, rapid reversal modality for major bleeding events in the presence of warfarin and an elevated INR. The agent's response is quicker than that expected with fresh frozen plasma combined with vitamin K. In emergency situations, rFVIIa 1.2 mg can be used to reverse the anticoagulant effect of warfarin and other vitamin K antagonists without inducing a hypercoagulable state; the product, however, is expensive.",
keywords = "Anticoagulation reversal, Bleeding, Fresh frozen plasma, INR, International normalized ratio, Intracranial hemorrhage, NOVOSEVEN, Recombinant activated factor VII, rFVIIa, Trauma, Warfarin",
author = "Dager, {William E.} and King, {Jeff H.} and Regalia, {Ron C.} and Dean Williamson and Gosselin, {Robert C.} and White, {Richard H} and Tharratt, {R. Steven} and Albertson, {Timothy E}",
year = "2006",
month = "8",
doi = "10.1592/phco.26.8.1091",
language = "English (US)",
volume = "26",
pages = "1091--1098",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8 I",

}

TY - JOUR

T1 - Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin

AU - Dager, William E.

AU - King, Jeff H.

AU - Regalia, Ron C.

AU - Williamson, Dean

AU - Gosselin, Robert C.

AU - White, Richard H

AU - Tharratt, R. Steven

AU - Albertson, Timothy E

PY - 2006/8

Y1 - 2006/8

N2 - Study Objective. To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events. Design. Prospective observational study. Setting. Intensive care unit of a 500-bed university-affiliated hospital. Patients. Sixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event. Intervention. Patients received rFVIIa 1.2 mg for reversal of anticoagulation. Measurements and Main Results. Patients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross-checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean ± SD dose of rFVIIa 16.3 ± 4.1 μg/kg (range 11-25 μg/kg) reduced the mean INR from 2.8 ± 1.6 (range 1.44-6.34) to 1.07 ± 0.27 (range 0.86-1.92, p<0.001). A rapid onset of response for achieving a desirable hemostatic effect was observed in 14 of the 16 patients. Conclusion. Low-dose rFVIIa appears to be an effective, rapid reversal modality for major bleeding events in the presence of warfarin and an elevated INR. The agent's response is quicker than that expected with fresh frozen plasma combined with vitamin K. In emergency situations, rFVIIa 1.2 mg can be used to reverse the anticoagulant effect of warfarin and other vitamin K antagonists without inducing a hypercoagulable state; the product, however, is expensive.

AB - Study Objective. To assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events. Design. Prospective observational study. Setting. Intensive care unit of a 500-bed university-affiliated hospital. Patients. Sixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event. Intervention. Patients received rFVIIa 1.2 mg for reversal of anticoagulation. Measurements and Main Results. Patients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross-checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean ± SD dose of rFVIIa 16.3 ± 4.1 μg/kg (range 11-25 μg/kg) reduced the mean INR from 2.8 ± 1.6 (range 1.44-6.34) to 1.07 ± 0.27 (range 0.86-1.92, p<0.001). A rapid onset of response for achieving a desirable hemostatic effect was observed in 14 of the 16 patients. Conclusion. Low-dose rFVIIa appears to be an effective, rapid reversal modality for major bleeding events in the presence of warfarin and an elevated INR. The agent's response is quicker than that expected with fresh frozen plasma combined with vitamin K. In emergency situations, rFVIIa 1.2 mg can be used to reverse the anticoagulant effect of warfarin and other vitamin K antagonists without inducing a hypercoagulable state; the product, however, is expensive.

KW - Anticoagulation reversal

KW - Bleeding

KW - Fresh frozen plasma

KW - INR

KW - International normalized ratio

KW - Intracranial hemorrhage

KW - NOVOSEVEN

KW - Recombinant activated factor VII

KW - rFVIIa

KW - Trauma

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=33746712273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746712273&partnerID=8YFLogxK

U2 - 10.1592/phco.26.8.1091

DO - 10.1592/phco.26.8.1091

M3 - Article

C2 - 16863486

AN - SCOPUS:33746712273

VL - 26

SP - 1091

EP - 1098

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8 I

ER -